,,ii  #aahth ,,congress  #b;d ,session  
,s4 #deaj  ,,in ,,the ,,senate ,,of     
,,the ,,united ,,states  ,june #aa1     
#bjbd,mrs4 ,blackburn 7for herself and  
,mr4 ,lujn7 introduced the following    
bill2 which was read twice and referred 
to the ,committee on ,finance  ,a ,,bill
  ,to amend the ,american ,taxpayer     
,relief ,act of #bjab to delay          
implementation of the inclusion of      
oral-only ,,esrd-related drugs in the   
,medicare ,,esrd prospective payment    
system4  #a4 ,short title ,this ,act may
 be cited as the ,kidney ,patient       
,access to ,technologically ,innovative 
and ,essential ,nephrology ,treatments  
,act of #bjbd or the ,kidney ,,patient  
,act of #bjbd4  #b4 ,prohibition of     
implementation of oral-only policy for  
certain drugs under ,medicare ,,esrd    
prospective payment system  7a7 ,in     
general ,section #fcb7;b7 of the        
,american ,taxpayer ,relief ,act of     
#bjab 7#db ,u4,s4,c4 #acierr note7 is   
amended-- 7#a7 in the heading1 by       

striking ,two-year delay and inserting  
,delay2 and  7#b7 in the first sentence 
of paragraph 7#a71 by striking may not  
implement and all that follows through  
,january #a1 #bjbe4 and inserting may   
not implement the policy under section  
#dac4agd7;f77#f7 of title #db1 ,code of 
,federal ,regulations 7relating to      
oral-only ,,esrd-related drugs in the   
,,esrd prospective payment system7 with 
respect to such drugs indicated for the 
reduction1 management1 or control of the
 serum phosphate of an individual before
 ,january #a1 #bjbg44  7b7 ,study ,not  
later than #a year after the date of the
 enactment of this ,act1 the ,secretary 
of ,health and ,human ,services shall   
submit to ,congress and make available  
on the public website of the ,centers   
for ,medicare  ,medicaid ,services a    
report containing data from #bjbb       
through #bjbd on-- 7#a7 the number of   
individuals entitled to benefits under  
part ,a of title ,,xviii of the ,social 
,security ,act 7#db ,u4,s4,c4 #acie;c et

 seq47 or enrolled under part ,b of such
 title 7#db ,u4,s4,c4 #acie;j et seq47  
with end-stage renal disease who are    
enrolled under a prescription drug plan 
under part ,d of such title 7#db        
,u4,s4,c4 #aciew-#aja et seq47 or under 
an ,,ma-,,pd plan under part ,c of such 
title 7#db ,u4,s4,c4 #aciew-#ba et      
seq471 along with a specification of any
 gaps in coverage under such            
prescription drug plans or ,,ma-,,pd    
plans2  7#b7 the amount of expenditures 
under such part ,d attributable to      
oral-only drugs related to the treatment
 of end-stage renal disease and the     
amount of cost sharing incurred by such 
individuals for such drugs2  7#c7 such  
individuals' adherence to prescriptions 
for such drugs1 including as measured by
 serum phosphate levels1 reported       
through the end-stage renal disease     
quality reporting system2  7#d7 adverse 
events of such individuals related to   
hyperphosphatemia and estimated costs   
attributable to such adverse events     

under such title2 and  7#e7 any         
recommended strategies or standards of  
practice to increase adherence to       
prescribed phosphate binders or lowering
 agents or other strategies to reduce   
costs to such individuals and           
expenditures under such program for such
 agents4